(Q28533379)

English

Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction

scientific article

In more languages

Statements

scholarly article

0 references

6 references

24 March 2019

17 June 2019

25 June 2019

20 August 2019

22 January 2021

26 January 2021

systematic review

1 reference

based on heuristic

inferred from title

0 references

Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction (English)

0 references

anti-retroviral agent

0 references

4 references

24 March 2019

17 June 2019

25 June 2019

20 August 2019

physiological phenomenon

1 reference

20 August 2019

highly active antiretroviral therapy

2 references

22 January 2021

26 January 2021

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Karen Cohen

2

0 references

object named as

Gary Maartens

3

0 references

object named as

Reneé de Waal

1

1 reference

ORCID Public Data File 2021

language of work or name

0 references

publication date

28 May 2013

6 references

24 March 2019

17 June 2019

25 June 2019

20 August 2019

22 January 2021

26 January 2021

6 references

24 March 2019

17 June 2019

25 June 2019

20 August 2019

22 January 2021

26 January 2021

8

0 references

5

0 references

e63623

0 references

copyright license

Creative Commons Attribution 4.0 International

6 references

Europe PubMed Central

24 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

20 August 2019

Europe PubMed Central

22 January 2021

Europe PubMed Central

26 January 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Fat distribution in men with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

29 September 2017

Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

2 June 2018

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

2 June 2018

Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

Body composition changes after switching from protease inhibitors to raltegravir

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0063623

21 January 2018

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

27 November 2018

Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3665842

27 November 2018

A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23723990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between HAART adherence and adipose tissue alterations

1 reference

https://pubmed.ncbi.nlm.nih.gov/23723990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0063623

0 references

2013PLoSO...863623D

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28533379&oldid=1954706123"